Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Graefen

Showing results (601-610 of 850) with videos related to

Pageof 85
Sort By:
BJU International|March 5, 2014
Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European studyNicola Fossati, Massimo Lazzeri, Alexander Haese, et al.
Experimental and Molecular Pathology|August 17, 2013
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomyKatharina Grupp, Thorsten Simon Höhne, Kristina Prien, et al.
World Journal of Urology|January 27, 2022
Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patientsGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
The Journal of Urology|September 24, 2021
Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate CancerFrancesco Chierigo, Mike Wenzel, Christoph Würnschimmel, et al.
European Urology Focus|April 15, 2021
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysisMike Wenzel, Christoph Würnschimmel, Luigi Nocera, et al.
Journal of Endourology|July 14, 2009
Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapyHendrik Isbarn, Claudio Jeldres, Umberto Capitanio, et al.
BMC Cancer|June 2, 2018
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancerMarie-Christine Heinrich, Cosima Göbel, Martina Kluth, et al.
The Prostate|May 31, 2021
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patternsChristoph Würnschimmel, Mike Wenzel, Francesco Chierigo, et al.
Frontiers in Oncology|December 23, 2022
Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerationsLuigi Nocera, Lara F Stolzenbach, Claudia Collà Ruvolo, et al.
International Journal of Cancer|May 27, 2015
Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancerMartina Kluth, Frederic Runte, Philipp Barow, et al.
Pageof 85

Showing results (601-610 of 850) with videos related to

Sort By:
Pageof 85
BJU International|March 5, 2014
Clinical performance of serum isoform [-2]proPSA (p2PSA), and its derivatives %p2PSA and the Prostate Health Index, in men aged <60 years: results from a multicentric European studyNicola Fossati, Massimo Lazzeri, Alexander Haese, et al.
Experimental and Molecular Pathology|August 17, 2013
Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomyKatharina Grupp, Thorsten Simon Höhne, Kristina Prien, et al.
World Journal of Urology|January 27, 2022
Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patientsGabriele Sorce, Rocco Simone Flammia, Benedikt Hoeh, et al.
The Journal of Urology|September 24, 2021
Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate CancerFrancesco Chierigo, Mike Wenzel, Christoph Würnschimmel, et al.
European Urology Focus|April 15, 2021
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysisMike Wenzel, Christoph Würnschimmel, Luigi Nocera, et al.
Journal of Endourology|July 14, 2009
Thirty-day mortality after transurethral resection of the prostate in patients treated with androgen deprivation therapyHendrik Isbarn, Claudio Jeldres, Umberto Capitanio, et al.
BMC Cancer|June 2, 2018
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancerMarie-Christine Heinrich, Cosima Göbel, Martina Kluth, et al.
The Prostate|May 31, 2021
Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patternsChristoph Würnschimmel, Mike Wenzel, Francesco Chierigo, et al.
Frontiers in Oncology|December 23, 2022
Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerationsLuigi Nocera, Lara F Stolzenbach, Claudia Collà Ruvolo, et al.
International Journal of Cancer|May 27, 2015
Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancerMartina Kluth, Frederic Runte, Philipp Barow, et al.
Pageof 85